Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

I-123-MIBG for detection of subacute doxorubicin-induced cardiotoxicity in patients with malignant lymphoma

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Rubidium-82 positron emission tomography for detection of acute doxorubicin-induced cardiac effects in lymphoma patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Stomach interference in 82Rb-PET myocardial perfusion imaging

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Doxorubicin is the mainstay of curative lymphoma treatment but is associated with a dose-dependent cardiotoxicity that is often recognized too late to avoid substantial irreversible cardiac injury. Iodine-123 metaiodobenzylguanidine (123I-MIBG) is a gamma-emitting tracer that mimics noradrenaline uptake, storage, and release mechanisms in adrenergic presynaptic neurons. 123I-MIBG scintigraphy can be used for assessment of doxorubicin-induced injury to myocardial adrenergic neurons during treatment and could be the tool for early detection of doxorubicin cardiotoxicity, which is currently lacking.

METHODS AND RESULTS: A total of 37 lymphoma patients scheduled for doxorubicin treatment were included in our study. 123I-MIBG imaging was performed prior to chemotherapy and after a median of 4 cycles of doxorubicin. Early and late heart-to-mediastinum ratios (H/Mearly and H/Mlate) and washout rate (WOR) were used for evaluation of cardiotoxicity. The prognostic value of 123I-MIBG results was assessed using left ventricular ejection fraction (LVEF) as measured by cardiac magnetic resonance at 1-year follow-up. We found a post-therapy increase in WOR (including nine patients with > 10% increase), which was not statistically significant (18.6 vs 23.4%, P = 0.09). The difference appeared to be driven by an increase in H/Mearly. LVEF decreased from baseline to 1-year follow-up (64 vs 58%, P = 0.03). LVEF change was not associated with changes in WOR (P = 0.5).

CONCLUSION: The present study does not provide evidence for 123I-MIBG imaging as a clinically applicable tool for early detection of doxorubicin-induced cardiotoxicity.

Original languageEnglish
JournalJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
Issue number3
Pages (from-to)931-939
Number of pages9
Publication statusPublished - Jun 2020

    Research areas

  • I-MIBG, cardiotoxicity, doxorubicin, lymphoma, sympathetic nervous system, I-123-MIBG

ID: 56242040